MedTrace Logo

Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke

NCT00721357 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-03-18

Study results available
· View outcomes & findings →

Summary

Of the \~700,000 persons who suffer a stroke each year, only 50% recover the ability to perform unlimited community walking. One mechanism contributing to locomotor dysfunction post-stroke is an increased metabolic cost of walking relative to neurologically healthy individuals 2-4. This increased cost likely limits the amount of walking performed, which further reduces functional capacity, thus contributing to long-term spiral of disability and decreased quality of life in these persons. In addition to increased metabolic cost, increased estimates of mechanical work are also characteristic of hemiparetic walking 2,29. Interestingly, although estimates of mechanical work reflect work done by locomotor muscles, little is known about the impact that peripheral muscle properties have on estimates of mechanical work. Furthermore, questions concerning how these properties relate to the increased metabolic cost of walking remain unanswered. The short-term objective and purpose of the proposed research is to determine the extent to which peripheral muscle characteristics, as well as estimates of muscle mechanical energy expenditure (MMEE), relate to the metabolic cost of walking post-stroke.

Conditions

Interventions

BEHAVIORAL

Treadmill walking

Subjects will perform treadmill walking at a self-selected velocity

OTHER

Magnetic resonance spectroscopy

Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)

Sponsors & Collaborators

  • Medical University of South Carolina

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Chris M. Gregory, PhD · Ralph H. Johnson VA Medical Center, Charleston, SC

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-07-31
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00721357 on ClinicalTrials.gov